Rinvoq Achieved Clinical Remission and Endoscopic Response at One Year in Phase 3 Maintenance Study in Patients with Crohn ' s Disease

NORTH CHICAGO, Ill., May 11, 2022. AbbVie today announced positive topline results from U-ENDURE, its Phase 3 maintenance study evaluating upadacitinib in adult patients with moderate to severe Crohn ' s disease who had an inadequate response or were...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials